



ASX & Media Release

Patrys Receives R&D Tax Incentive Refund

Melbourne, Australia, 7 November 2019: Patrys Limited (ASX:PAB, "Patrys" or the "Company"), a therapeutic antibody development company, is pleased to announce it has received a \$672,143 R&D Tax Incentive Refund for the 2018/2019 financial year.

Patrys Chief Executive Officer and Managing Director, Dr. James Campbell said: "The receipt of the R&D rebate strengthens our financial position and will support progression towards the clinic of PAT-DX1 in the coming year."

The R&D Tax Incentive Refund is an Australian Government program that supports companies engaging in R&D activities in Australia, by providing a tax offset of up to 43.5% of eligible expenditure on R&D activities.

-Ends-

To learn more please visit: www.patrys.com

For further information, please contact:

General enquiries

James Campbell
Chief Executive Officer
P: +61 3 9670 3273
info@patrys.com

Media enquiries:

Kyahn Williamson
Buchan Consulting
P: +61 3 9866 4722
kwilliamson@we-buchan.com

About Patrys Limited

Based in Melbourne, Australia, Patrys (ASX:PAB) is focused on the development of antibodies as therapies for a range of different cancers. Patrys has a pipeline of anti-cancer antibodies for both internal development and as partnering opportunities. More information can be found at www.patrys.com.